2Q Revenues: $59.3 million (+19%)
2Q Loss: $2.2 million (earnings were $297k in 2Q12)
YTD Revenues: $118.7 million (+14%)
YTD Earnings: $4.3 million (loss of $3.6 million YTD12)
Comments: Contract revenue for the quarter was $50.8 million, up 20%, with Discovery Services revenue up 26% to $10.8 million; Development/Small Scale Manufacturing revenue up 7% to $8.7 million; and Large Scale Manufacturing revenue up 22% to $31.3 million. Royalty revenue in the quarter was $8.5 million, up 13%, which includes royalties from Allegra products, as well as $2.8 million from sales of certain amphetamine salts sold by Actavis. Loss in the quarter is primarily related to restructuring and associated asset impairment charges related to the company's decision to consolidate its Discovery Services platform.